Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
C4 Therapeutics, Inc. (NASDAQ: CCCC)
CCCC Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-15.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
151.50%
CCCC Stock Analysis
CCCC
PE Ratio:
CCCC
PEG Ratio:
Not Available
CCCC
Forward EPS Growth (12 month):
0.00%
CCCC
PS Ratio:
9.4
CCCC
PSG Ratio:
-1
CCCC
Forward Revenue Growth (12 month):
-9.20%
CCCC Articles
No data was found